{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:18:19Z","timestamp":1791555499473,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG044546"],"award-info":[{"award-number":["R01AG044546"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG053303"],"award-info":[{"award-number":["RF1AG053303"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG058501"],"award-info":[{"award-number":["R01AG058501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG058922"],"award-info":[{"award-number":["U01AG058922"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG058501"],"award-info":[{"award-number":["RF1AG058501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG057777"],"award-info":[{"award-number":["R01AG057777"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13024-019-0319-3","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T05:03:45Z","timestamp":1557291825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers"],"prefix":"10.1186","volume":"14","author":[{"given":"Jorge L.","family":"Del-Aguila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno A.","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umber","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie A.","family":"Mihindukulasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana H. G.","family":"Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel J.","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-2899","authenticated-orcid":false,"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"319_CR1","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.4049\/jimmunol.164.10.4991","volume":"164","author":"A Bouchon","year":"2000","unstructured":"Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164:4991\u20135.","journal-title":"J Immunol"},{"key":"319_CR2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1084\/jem.194.8.1111","volume":"194","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, Hernandez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194:1111\u201322.","journal-title":"J Exp Med"},{"key":"319_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2006.11.032","volume":"184","author":"H Neumann","year":"2007","unstructured":"Neumann H, Takahashi K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol. 2007;184:92\u20139.","journal-title":"J Neuroimmunol"},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0040124","volume":"4","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med. 2007;4:e124.","journal-title":"PLoS Med"},{"key":"319_CR5","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni1411","volume":"7","author":"J Klesney-Tait","year":"2006","unstructured":"Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266\u201373.","journal-title":"Nat Immunol"},{"key":"319_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1212\/01.WNL.0000160304.00003.CA","volume":"64","author":"HH Klunemann","year":"2005","unstructured":"Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor MN, Marienhagen J, Klein HE, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502\u20137.","journal-title":"Neurology"},{"key":"319_CR7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1086\/342259","volume":"71","author":"J Paloneva","year":"2002","unstructured":"Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656\u201362.","journal-title":"Am J Hum Genet"},{"key":"319_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11064-008-9657-1","volume":"34","author":"JC Thrash","year":"2009","unstructured":"Thrash JC, Torbett BE, Carson MJ. Developmental regulation of TREM2 and DAP12 expression in the murine CNS: implications for Nasu-Hakola disease. Neurochem Res. 2009;34:38\u201345.","journal-title":"Neurochem Res"},{"key":"319_CR9","doi-asserted-by":"publisher","first-page":"1711 e1715","DOI":"10.1016\/j.neurobiolaging.2012.12.018","volume":"34","author":"BA Benitez","year":"2013","unstructured":"Benitez BA, Cooper B, Pastor P, Jin SC, Lorenzo E, Cervantes S, Cruchaga C. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging. 2013;34:1711 e1715\u20137.","journal-title":"Neurobiol Aging"},{"key":"319_CR10","doi-asserted-by":"publisher","first-page":"1510 e1519","DOI":"10.1016\/j.neurobiolaging.2013.12.010","volume":"35","author":"BA Benitez","year":"2014","unstructured":"Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging. 2014;35:1510 e1519\u201326.","journal-title":"Neurobiol Aging"},{"key":"319_CR11","doi-asserted-by":"publisher","first-page":"726 e711","DOI":"10.1016\/j.neurobiolaging.2013.09.009","volume":"35","author":"E Cuyvers","year":"2014","unstructured":"Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35:726 e711\u201329.","journal-title":"Neurobiol Aging"},{"key":"319_CR12","doi-asserted-by":"publisher","first-page":"546 e549","DOI":"10.1016\/j.neurobiolaging.2014.08.001","volume":"36","author":"D Finelli","year":"2015","unstructured":"Finelli D, Rollinson S, Harris J, Jones M, Richardson A, Gerhard A, Snowden J, Mann D, Pickering-Brown S. TREM2 analysis and increased risk of Alzheimer's disease. Neurobiol Aging. 2015;36:546 e549\u201313.","journal-title":"Neurobiol Aging"},{"issue":"217","key":"319_CR13","first-page":"e217","volume":"42","author":"M Ghani","year":"2016","unstructured":"Ghani M, Sato C, Kakhki EG, Gibbs JR, Traynor B, St George-Hyslop P, Rogaeva E. Mutation analysis of the MS4A and TREM gene clusters in a case-control Alzheimer's disease data set. Neurobiol Aging. 2016;42(217):e217\u2013217 e213.","journal-title":"Neurobiol Aging"},{"key":"319_CR14","doi-asserted-by":"publisher","first-page":"2077 e2011","DOI":"10.1016\/j.neurobiolaging.2013.02.016","volume":"34","author":"M Giraldo","year":"2013","unstructured":"Giraldo M, Lopera F, Siniard AL, Corneveaux JJ, Schrauwen I, Carvajal J, Munoz C, Ramirez-Restrepo M, Gaiteri C, Myers AJ, et al. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging. 2013;34:2077 e2011\u201378.","journal-title":"Neurobiol Aging"},{"key":"319_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117\u201327.","journal-title":"N Engl J Med"},{"key":"319_CR16","doi-asserted-by":"publisher","first-page":"217 e211","DOI":"10.1016\/j.neurobiolaging.2016.02.029","volume":"42","author":"T Jiang","year":"2016","unstructured":"Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD, Yu JT. A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiol Aging. 2016;42:217 e211\u20133.","journal-title":"Neurobiol Aging"},{"key":"319_CR17","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","volume":"23","author":"SC Jin","year":"2014","unstructured":"Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet. 2014;23:5838\u201346.","journal-title":"Hum Mol Genet"},{"key":"319_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107\u201316.","journal-title":"N Engl J Med"},{"key":"319_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jalz.2014.12.009","volume":"11","author":"CM Lill","year":"2015","unstructured":"Lill CM, Rengmark A, Pihlstrom L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's Dement. 2015;11:1407\u201316.","journal-title":"Alzheimer's Dement"},{"key":"319_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000430842","volume":"24","author":"Z Mehrjoo","year":"2015","unstructured":"Mehrjoo Z, Najmabadi A, Abedini SS, Mohseni M, Kamali K, Najmabadi H, Khorram Khorshid HR. Association study of the TREM2 gene and Identification of a novel variant in exon 2 in Iranian patients with late-onset Alzheimer's disease. Med Princ Pract. 2015;24:351\u20134.","journal-title":"Med Princ Pract"},{"key":"319_CR21","doi-asserted-by":"publisher","first-page":"2443 e2421","DOI":"10.1016\/j.neurobiolaging.2015.04.012","volume":"36","author":"SL Rosenthal","year":"2015","unstructured":"Rosenthal SL, Bamne MN, Wang X, Berman S, Snitz BE, Klunk WE, Sweet RA, Demirci FY, Lopez OL, Kamboh MI. More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol Aging. 2015;36:2443 e2421\u201346.","journal-title":"Neurobiol Aging"},{"key":"319_CR22","doi-asserted-by":"publisher","first-page":"444 e441","DOI":"10.1016\/j.neurobiolaging.2014.06.016","volume":"35","author":"A Ruiz","year":"2014","unstructured":"Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodriguez-Rodriguez E, Lopez de Munain A, de Pancorbo MM, Perez-Tur J, Alvarez V, Antonell A, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol Aging. 2014;35:444 e441\u20134.","journal-title":"Neurobiol Aging"},{"key":"319_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jalz.2014.05.1751","volume":"10","author":"CF Slattery","year":"2014","unstructured":"Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer JD, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's Dement. 2014;10:602\u2013608 e604.","journal-title":"Alzheimer's Dement"},{"key":"319_CR24","first-page":"937 e931","volume":"35","author":"JT Yu","year":"2014","unstructured":"Yu JT, Jiang T, Wang YL, Wang HF, Zhang W, Hu N, Tan L, Sun L, Tan MS, Zhu XC, Tan L. Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiol Aging. 2014;35:937 e931\u20133.","journal-title":"Neurobiol Aging"},{"key":"319_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jalz.2014.10.013","volume":"11","author":"P Roussos","year":"2015","unstructured":"Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimer's Dement. 2015;11:1163\u201370.","journal-title":"Alzheimer's Dement"},{"key":"319_CR26","doi-asserted-by":"publisher","first-page":"12634","DOI":"10.1074\/jbc.RA118.002352","volume":"293","author":"A Sudom","year":"2018","unstructured":"Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, Richardson J, Zhang Z, Sharkov N, Marcora E, et al. Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2. J Biol Chem. 2018;293:12634\u201346.","journal-title":"J Biol Chem"},{"key":"319_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160:1061\u201371.","journal-title":"Cell"},{"key":"319_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-Beta by microglia. Neuron. 2016;91:328\u201340.","journal-title":"Neuron"},{"key":"319_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neuron.2018.01.031","volume":"97","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Pina-Crespo JC, Zhang M, et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97:1023\u201331 e1027.","journal-title":"Neuron"},{"key":"319_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.20171529","volume":"215","author":"WM Song","year":"2018","unstructured":"Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215:745\u201360.","journal-title":"J Exp Med"},{"key":"319_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-018-0262-8","volume":"13","author":"PJ Cheng-Hathaway","year":"2018","unstructured":"Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von Saucken VE, Williams RY, Karlo JC, Moutinho M, et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease. Mol Neurodegener. 2018;13:29.","journal-title":"Mol Neurodegener"},{"key":"319_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13024-018-0280-6","volume":"13","author":"X Xiang","year":"2018","unstructured":"Xiang X, Piers TM, Wefers B, Zhu K, Mallach A, Brunner B, Kleinberger G, Song W, Colonna M, Herms J, et al. The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. Mol Neurodegener. 2018;13:49.","journal-title":"Mol Neurodegener"},{"key":"319_CR33","doi-asserted-by":"publisher","unstructured":"Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, Brett TJ. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. eLife. 2016;5:e20391. \n                    https:\/\/doi.org\/10.7554\/eLife.20391\n                    \n                  .","DOI":"10.7554\/eLife.20391"},{"key":"319_CR34","doi-asserted-by":"publisher","first-page":"243ra286","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.","journal-title":"Sci Transl Med"},{"key":"319_CR35","doi-asserted-by":"publisher","first-page":"33027","DOI":"10.1074\/jbc.M113.517540","volume":"288","author":"P Wunderlich","year":"2013","unstructured":"Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem. 2013;288:33027\u201336.","journal-title":"J Biol Chem"},{"key":"319_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925\u201333.","journal-title":"Acta Neuropathol"},{"key":"319_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"319_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479\u201386.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"319_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1017\/S1041610297004870","volume":"9","author":"JC Morris","year":"1997","unstructured":"Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(Suppl 1):173\u20136; discussion 177-178.","journal-title":"Int Psychogeriatr"},{"key":"319_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JAD-150252","volume":"49","author":"BE Gavett","year":"2016","unstructured":"Gavett BE, John SE, Gurnani AS, Bussell CA, Saurman JL. The role of Alzheimer's and cerebrovascular pathology in mediating the effects of age, race, and apolipoprotein E genotype on dementia severity in pathologically-confirmed Alzheimer's disease. J Alzheimer's Dis. 2016;49:531\u201345.","journal-title":"J Alzheimer's Dis"},{"key":"319_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13073-018-0551-4","volume":"10","author":"Z Li","year":"2018","unstructured":"Li Z, Del-Aguila JL, Dube U, Budde J, Martinez R, Black K, Xiao Q, Cairns NJ, Dominantly Inherited Alzheimer N, Dougherty JD, et al. Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med. 2018;10:43.","journal-title":"Genome Med"},{"key":"319_CR42","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1896849","volume":"253","author":"LR Squire","year":"1991","unstructured":"Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253:1380\u20136.","journal-title":"Science"},{"key":"319_CR43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/cercor\/6.6.823","volume":"6","author":"GK Aguirre","year":"1996","unstructured":"Aguirre GK, Detre JA, Alsop DC, D'Esposito M. The parahippocampus subserves topographical learning in man. Cereb Cortex. 1996;6:823\u20139.","journal-title":"Cereb Cortex"},{"key":"319_CR44","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0028-3932(96)00022-X","volume":"34","author":"EA Maguire","year":"1996","unstructured":"Maguire EA, Burke T, Phillips J, Staunton H. Topographical disorientation following unilateral temporal lobe lesions in humans. Neuropsychologia. 1996;34:993\u20131001.","journal-title":"Neuropsychologia"},{"key":"319_CR45","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3233\/JAD-170834","volume":"62","author":"JL Del-Aguila","year":"2018","unstructured":"Del-Aguila JL, Fernandez MV, Schindler S, Ibanez L, Deming Y, Ma S, Saef B, Black K, Budde J, Norton J, et al. Assessment of the genetic architecture of Alzheimer's disease risk in rate of memory decline. J Alzheimer's Dis. 2018;62:745\u201356.","journal-title":"J Alzheimer's Dis"},{"key":"319_CR46","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/ejhg.2016.122","volume":"24","author":"MV Fernandez","year":"2016","unstructured":"Fernandez MV, Black K, Carrell D, Saef B, Budde J, Deming Y, Howells B, Del-Aguila JL, Ma S, Bi C, et al. SORL1 variants across Alzheimer's disease European American cohorts. Eur J Hum Genet. 2016;24:1828\u201330.","journal-title":"Eur J Hum Genet"},{"key":"319_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3389\/fnins.2018.00209","volume":"12","author":"MV Fernandez","year":"2018","unstructured":"Fernandez MV, Budde J, Del-Aguila JL, Ibanez L, Deming Y, Harari O, Norton J, Morris JC, Goate AM, Group N-Lfs, et al. Evaluation of gene-based family-based methods to detect novel genes associated with familial late onset Alzheimer disease. Front Neurosci. 2018;12:209.","journal-title":"Front Neurosci"},{"key":"319_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007045","volume":"13","author":"MV Fernandez","year":"2017","unstructured":"Fernandez MV, Kim JH, Budde JP, Black K, Medvedeva A, Saef B, Deming Y, Del-Aguila J, Ibanez L, Dube U, et al. Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer disease. PLoS Genet. 2017;13:e1007045.","journal-title":"PLoS Genet"},{"key":"319_CR49","unstructured":"FastQC A Quality Control tool for high throughput sequence data [\n                    http:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/\n                    \n                   ]."},{"key":"319_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525\u20137.","journal-title":"Nat Biotechnol"},{"key":"319_CR51","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Research. 2015;4:1521.","journal-title":"F1000Research"},{"key":"319_CR52","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, Rinker J 2nd, Naismith RT, Panina-Bordignon P, Passini N, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131:3081\u201391.","journal-title":"Brain"},{"key":"319_CR53","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1038\/s41598-017-06710-1","volume":"7","author":"BA Benitez","year":"2017","unstructured":"Benitez BA, Sands MS. Primary fibroblasts from CSPalpha mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis. Sci Rep. 2017;7:6332.","journal-title":"Sci Rep"},{"key":"319_CR54","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/14728222.2018.1486823","volume":"22","author":"Y Deming","year":"2018","unstructured":"Deming Y, Li Z, Benitez BA, Cruchaga C. Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease? Expert Opin Ther Targets. 2018;22:587\u201398.","journal-title":"Expert Opin Ther Targets"},{"key":"319_CR55","first-page":"1567","volume":"369","author":"BA Benitez","year":"2013","unstructured":"Benitez BA, Cruchaga C. United States-Spain Parkinson's disease research G: TREM2 and neurodegenerative disease. N Engl J Med. 2013;369:1567\u20138.","journal-title":"N Engl J Med"},{"key":"319_CR56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaneurol.2013.6237","volume":"71","author":"J Cady","year":"2014","unstructured":"Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449\u201353.","journal-title":"JAMA Neurol"},{"key":"319_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fncel.2018.00206","volume":"12","author":"H Konishi","year":"2018","unstructured":"Konishi H, Kiyama H. Microglial TREM2\/DAP12 signaling: a double-edged sword in neural diseases. Front Cell Neurosci. 2018;12:206.","journal-title":"Front Cell Neurosci"},{"key":"319_CR58","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.4049\/jimmunol.177.4.2051","volume":"177","author":"JA Hamerman","year":"2006","unstructured":"Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol. 2006;177:2051\u20135.","journal-title":"J Immunol"},{"key":"319_CR59","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/eji.200636837","volume":"37","author":"L Piccio","year":"2007","unstructured":"Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37:1290\u2013301.","journal-title":"Eur J Immunol"},{"key":"319_CR60","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.4049\/jimmunol.177.6.3520","volume":"177","author":"IR Turnbull","year":"2006","unstructured":"Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520\u20134.","journal-title":"J Immunol"},{"key":"319_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep38761","volume":"6","author":"H Jiang","year":"2016","unstructured":"Jiang H, Si Y, Li Z, Huang X, Chen S, Zheng Y, Xu G, Chen X, Chen Y, Liu Y, et al. TREM-2 promotes acquired cholesteatoma-induced bone destruction by modulating TLR4 signaling pathway and osteoclasts activation. Sci Rep. 2016;6:38761.","journal-title":"Sci Rep"},{"key":"319_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13148-016-0202-9","volume":"8","author":"N Celarain","year":"2016","unstructured":"Celarain N, Sanchez-Ruiz de Gordoa J, Zelaya MV, Roldan M, Larumbe R, Pulido L, Echavarri C, Mendioroz M. TREM2 upregulation correlates with 5-hydroxymethycytosine enrichment in Alzheimer's disease hippocampus. Clin Epigenetics. 2016;8:37.","journal-title":"Clin Epigenetics"},{"key":"319_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-016-0137-9","volume":"11","author":"L Ma","year":"2016","unstructured":"Ma L, Allen M, Sakae N, Ertekin-Taner N, Graff-Radford NR, Dickson DW, Younkin SG, Sevlever D. Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Mol Neurodegener. 2016;11:72.","journal-title":"Mol Neurodegener"},{"key":"319_CR64","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.15252\/emmm.201707673","volume":"9","author":"P Thornton","year":"2017","unstructured":"Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, Franssen EH, Dodd RB, Qamar S, Gomez Perez-Nievas B, et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant. EMBO Mol Med. 2017;9:1366\u201378.","journal-title":"EMBO Mol Med"},{"key":"319_CR65","doi-asserted-by":"crossref","unstructured":"Deming Y, Filipello F, Cignarella F, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Cantoni C, et al. The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk. Sci Transl Med. 2019. manuscript #aau2291.","DOI":"10.1101\/352179"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-019-0319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-019-0319-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-019-0319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T06:20:08Z","timestamp":1589523608000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-019-0319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,8]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1186\/s13024-019-0319-3","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,8]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of Knight-ADRC studies have been approved by the review board of Washington University in St. Louis. The protocol of Mayo dataset was approved by the Mayo Clinic Institutional Review Board (IRB). All neuropsychological, diagnostic and autopsy protocols of MSSM dataset were approved by the Mount Sinai and JJ Peters VA Medical Center Institutional Review Boards. The MSSM sample protocol was approved by Icahn School of Medicine at Mount Sinai IRB; All participants were recruited with informed consent for research use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of ADx Healthcare, and Vivid Genomics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}